[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557560":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":26,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":64,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Saglik Bilimleri Universitesi","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"2\u002FGroup B (Benign), Group M (Malign)",null,"Mean Platelet Volume (MPV), Neutrophil\u002Flymphocyte Ratio (NLR), Platelet\u002FLymphocyte Ratio (PLR) and Lymphocyte\u002FMonocyte Ratio (LMR) will be recorded in preoperative hemograms. Among the patients included in the study, BRAF molecular testing will be performed on the preoperative cytology of 25 patients whose thyroidectomy materials were reported to be malignant. with thyroid nodule identified by Bethesda 3 cytology were examined retrospectively. According to the pathology results, they were divided into 2 groups: benign and malignant.\n\nGroup B (Benign);Preoperative hemogram parameters, Bethesda 3 cytology, Thyroidectomy, benign pathology.\n\nGroup M (Malign);Preoperative hemogram parameters, Betheda 3 cytology, Thyroidectomy, malign pathology, BRAF molecular test",[13],{"name":14,"affiliation":15,"role":16},"Ugur Kesici, Assoc.Prof.","Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization","PRINCIPAL_INVESTIGATOR",[18,24],{"name":19,"role":20,"phone":21,"phoneExt":22,"email":23},"Ugur 1 Kesici, Assoc. Prof.","CONTACT","00905445474710","50124","ugur.kesici@sbu.edu.tr",{"name":19,"role":20,"phone":21,"phoneExt":22,"email":25},"ugurkesici77@mynet.com",[27],{"facility":28,"status":29,"city":30,"state":10,"zip":31,"country":32,"countryCode":10,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Prof. Dr. Cemil Tascioglu City Hospital","RECRUITING","Istanbul","34000","Turkey (Türkiye)",{"type":34,"coordinates":35},"Point",[36,37],28.94966,41.01384,{"lat":37,"lon":36},[40,43,45],{"name":41,"role":20,"phone":42,"phoneExt":10,"email":25},"Ugur Kesici, Assoc. Prof","05445474710",{"name":10,"role":20,"phone":10,"phoneExt":44,"email":25},"Kesici",{"name":46,"role":16,"phone":10,"phoneExt":10,"email":10},"Ugur Kesici",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100557560","preoperative-hemogram-parameters-and-braf-molecular-test-detected-by-bethesda-3-cytology-100557560",false,"NCT06539702","Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology.","To Reveal the Predictive Value of Preoperative Hemogram Parameters and BRAF Molecular Test in Predicting Malignancy in Cases With Thyroid Nodules Detected by Bethesda 3 Cytology.","Bethesda3","Inclusion Criteria:\n\n1. Patients between the ages of 18 -75\n2. Patients who were diagnosed with Bethesda III as a result of preoperative FNAC and decided to undergo thyroidectomy\n\nExclusion Criteria:\n\n1. Patients over 18 years old and under 75 years old\n2. Patients with malignancy detected in another focus with preoperative Bethesda III FNAC\n3. Detection of malignancy in another focus other than the nodule with Bethesda III cytological result after thyroidectomy\n4. Failure to obtain preoperative hemogram results Patients who do not agree to participate in scientific studies for BRAF testing",true,"ALL","18 Years","75 Years",{"count":62,"type":63},120,"ESTIMATED","7 Days","OBSERVATIONAL","The main hypothesis of this study is that preoperative hemogram parameters can be used as biomarkers for malignancy in patients with thyroid nodule Bethesda 3 cytology.\n\nThe secondary hypothesis is that BRAF molecular testing has a high predictive value in predicting malignancy in patients with thyroid nodule Bethesda 3 cytology.\n\nPrimary outcome: Preoperative hemogram parameters. Secondary outcome: BRAF positivity.",[68,69,70,71],"Blood Platelet Disorder","BRAF V600E","Thyroid Nodule","Cytologic Atypia",[73,74,75,76],"Thyroid","carcinoma","Bethesda 3","BRAF","2024-08-01",{"date":79,"type":80},"2024-08-06","ACTUAL",{"date":82,"type":80},"2024-07-20",{"date":84,"type":63},"2024-08-15",{"name":5,"class":6},1]